RxDoctor Payments DataLook up a doctor →

John Ryan

Cardiovascular Disease · Salt Lake City, UTNPI 1902071673

Payments from drug & device makers

$4,224,666in general payments, 2019–2025

Across 1,556 payments — averaging $2715.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.5M
  • Actelion Pharmaceuticals US, Inc.$523K
  • United Therapeutics Corporation$306K
  • Bayer$242K
  • Janssen Research & Development, LLC$237K
  • Novartis$103K
  • plus $334K from 18 others

What the payments were for

  • Consulting fees$170,95412%
  • Speaking & faculty fees$1,009,18373%
  • Travel & lodging$182,60713%
  • Food & beverage$26,2492%
  • Education$1600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,224,666 in reported general payments places this provider in the 95th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$101,076
Medicare patients
1,501
Services billed
2,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan32$399,743
ArcalystRilonacept11$250,409
EntrestoSacubitril/Valsartan97$119,856
FarxigaDapagliflozin Propanediol73$60,447
JardianceEmpagliflozin45$59,298
EliquisApixaban27$20,516
Repatha SureclickEvolocumab30$20,461
Sildenafil Citrate22$3,249
Torsemide76$2,189
Potassium Chloride41$2,160
Bumetanide22$1,670
Spironolactone117$1,178
Atorvastatin Calcium82$710
Metoprolol Succinate47$648
Albuterol Sulfate HfaAlbuterol Sulfate12$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$522,657$399,74332 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$74,176$250,40911 claims
NovartisEntresto$102,866$119,85697 claims
AstraZenecaFarxiga$62$60,44773 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →